title: [Treatment option for pT3 patient after radical prostatectomy].
abstract: With the spread of prostate specific antigen (PSA) examination, radical cure treatment by radical prostatectomy has increased rapidly and the survival rate is high. However, about 26-68% of disease of clinical stage cT1-2 are diagnosed as pT3 in postoperative pathology. Although the 5-year PSA nonrecurrence rate is 91-97% for pT1-2, that for pT3 aN0 and pT3 bN0 is 76% and 37-40%, respectively. Appropriate adjuvant or salvage therapy for pT3 patient is necessary. However, at present the standard treatment method has not yet been established. In this report, radiation and hormone therapy are evaluated as postoperative supporting treatments for pT3 and the appropriate treatment to be taken for pT3 is summarized.
authors.affiliation: The Department of Urology, Mie University Faculty of Medicine.
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Sugimura
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Wakita
authors.forename: Atsushi
authors.initials: A
authors.lastname: Mizogam
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood; D017024:Chemotherapy, Adjuvant; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D009367:Neoplasm Staging; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000601:surgery / Q000628:therapy*; D018714:Radiotherapy, Adjuvant
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen